Alnylam Pharmaceuticals, Inc. (ALNY)

398.70 -9.03 (-2.21%) USD  |  NASDAQ  |  Dec 23, 16:00
397.78 -0.92 (-0.23%) Pre-Market: 08:53
More

Alnylam Pharmaceuticals SG&A Expense (TTM): 1.181B for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Biogen, Inc. 2.431B
Insmed, Inc. 631.20M
Pfizer Inc. 13.91B
Glaukos Corp. 306.05M
BridgeBio Pharma, Inc. 467.92M